Also known as: Novo Holdings
Servier agreed to acquire Day One for $2.5B, gaining an approved childhood brain tumor drug and pipeline assets. SCRI and MSD launched a collaboration to expand community oncology trial access, while Recursion took full ownership of REC-102 as Nvidia and Novo exited.
UK biotech financing jumped 17% to £552m in Q1 2026, capturing over half of European VC. Meanwhile, a new coalition of VCs managing €24 billion aims to reverse Europe's 7% share of global life sciences venture capital. Separately, CriteriaCaixa commits €300m for early-stage biotech and tech by 2030.
Novartis acquires UK biotech Myricx Bio for up to $1.5B, gaining a novel NMTi ADC payload platform and two lead assets targeting B7-H3 and HER2. The deal includes $1.1B upfront with $400M in milestones, expected to close in H2 2026.
New market reports project strong growth in pharmaceutical manufacturing: fill-finish is set to reach $21.04 billion by 2030, ampoule filling/sealing machines to grow at a 5.8% CAGR through 2035, and medical membranes to hit $6.6 billion by 2030.
Two major partnerships in India's diagnostics sector aim to strengthen precision medicine capabilities. MedGenome acquires majority stake in Medcare Management Services, while SRMIST partners with CORE Diagnostics to train future oncology professionals.
